Chesapeake Clinical Research, Inc. | White Marsh, MD

Research site

About

High level, experienced asthma/allergy/immunology site. Extensive experience in asthma, sinusitis, nasal polyposis, allergic rhinitis, eosinophilic disorders, urticaria and atopic dermatitis. We also work on vaccine trials and respiratory viral diseases.

Location

5430 Campbell Boulevard Suite #110, White Marsh, Maryland, United States of America

Site insights

Top conditions

Top treatments

MK-7264

UPB-101

Gefapixant

PF-04965842

Verekitug

CDX-0159

Rocatinlimab

BAY1817080

DUPIXENT®

MK-7264-043

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Jonathan Matz

Verified by this site

Active trials

8 of 20 total trials

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in...

Active, not recruiting

Chronic Spontaneous Urticaria

Biological: barzolvolimab

Drug: Matching Placebo

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Enrolling

Asthma

Drug: Placebo

Drug: Rocatinlimab

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria

This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism...

Enrolling

Chronic Inducible Urticaria

Drug: Oral EVO756

A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal pol...

Enrolling

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Drug: Standard therapy for INCS

Drug: LY3650150

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants with Severe Asthma (VALIANT)

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate t...

Enrolling

Severe Asthma

Drug: Placebo

Drug: Verekitug (UPB-101)

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants with Chronic Rhinosinusitis with Nasal Polyps (VIBRANT)

The primary purpose of this study is to assess the effect of verekitug (UPB-101) on the endoscopically determined size and extend of nasal polyps in...

Enrolling

Chronic Rhinosinusitis with Nasal Polyps

Drug: Placebo

Drug: Verekitug (UPB-101)

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria (CALM-CSU)

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urtica...

Enrolling

Chronic Spontaneous Urticaria

Drug: Placebo

Drug: Oral EP262

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting

Dermatitis, Atopic

Drug: Abrocitinib 200 mg

Drug: Abrocitinib 100 mg